IMPORTANCE Psoralen-UV-A (PUVA) photochemotherapy is standard first-line treatment for skin-limited, early-stage mycosis fungoides capable of producing high initial complete response (CR) rates. However, much remains unknown about PUVA's therapeutic mechanisms, optimal duration and frequency of treatment, dose escalation, or use as maintenance therapy.
M ycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, accounting for about twothirds of all cutaneous T-cell lymphomas and almost 50% of all primary cutaneous lymphomas. 1 It is characterized by the progressive evolution of erythematous patches, plaques, and tumors over years, eventually leading to metastasis and death.
In early MF disease stages, malignant T cells represent a minority of infiltrating T cells within the inflammatory cellular environment. 2 Lesional skin is characterized by the presence of small-to medium-sized T cells displaying the memory immunophenotype of CD3 + , CD4 + , and CD45RO + and, in most cases, clonal rearrangement of the T-cell receptor (TCR) gene. 3, 4 High-throughput TCR sequencing studies have shown that neoplastic cells arise from mature T lymphocytes and have helped to identify malignant clones, thereby facilitating their distinction from benign T-cell inflammatory diseases. 5 T cells that are isolated from MF lesions express CCR4 and the skin homing receptor CLA but lack CCR7/L-selectin and the differentiation marker CD27, a phenotype suggestive of skin-resident effector memory T cells. 6 Reports on the role of regulatory T-cells (Tregs) in MF are conflicting; in some cases, MF malignant clones share features with Tregs. 7 However, a Treg phenotype in malignant clones does not necessarily involve suppressive functionality. Early-stage MF is initially treated with skin-directed therapies that may include corticosteroids, chemotherapy, bexarotene, radiotherapy, and UV-B and psoralen-UV-A (PUVA) phototherapy.
9-11 More aggressive treatments are reserved for patients whose MF is more advanced or does not respond to skindirected therapies. 9, 12 Introduced in 1976, 13 PUVA is one of the most effective treatments for MF and is the standard first-line treatment for skin-limited MF (stages IA to IIA), with a complete response (CR) rate of 65% to 85%, depending on staging.
14 However, little is known about PUVA's therapeutic mechanisms or optimal dosing, duration and frequency of treatment (2, 3, or 4 times weekly), dose escalation, and maintenance therapy. 12,15-23 Whether PUVA maintenance therapy can prolong clinical response in MF on initial complete clearance is controversial. 24, 25 An online survey of 30 members of the International Society for Cutaneous Lymphoma revealed that 88% of respondents used some sort of PUVA maintenance therapy at frequencies ranging from weekly to monthly. 15 Despite this finding, the European Organisation for Research and Treatment of Cancer issued the recommendation to avoid maintenance because of unproven efficacy and safety concerns. 9 We carried out a prospective randomized clinical trial with low-dose, low-frequency oral PUVA with or without maintenance for patients with stage IA to IIA MF to evaluate its effectiveness and determine if maintenance extends disease-free remission. During this study, we also analyzed skin and blood samples to identify potential biomarkers for treatment response.
Methods

Study Design and Setup
The main aims of this randomized clinical trial were to determine the clinical response of patients with MF to oral PUVA (2 times/wk; start dose depending on minimal phototoxic dose [MPD] testing; weekly dose increments) and to investigate whether a maintenance regimen would prolong disease-free remission after CR. This study was carried out in accordance with the International Conference on Harmonization Good Clinical Practice guideline. 26 It received approval from the ethics committee of the Medical University of Graz and was in full compliance with the Austrian Medicinal Products Act. All participants gave written informed consent in accordance with the principles of the Declaration of Helsinki. 27 The trial protocol is provided in Supplement 1. During the PUVA induction phase, treatment was administered for 12 to 24 weeks until a modified severity-weighted assessment tool (mSWAT, a quantification of the body surface area of each lesion multiplied by a weighting factor for lesion type) 28 score was reduced to 0 and (whenever consented by the patient) confirmed by biopsy. Patients with CR were randomly assigned to receive either PUVA maintenance therapy for 9 months (arm A) or no maintenance (arm B) ( Figure 1 ). Patients with partial response (PR) were not randomized to either arm but were switched instead to an alternative therapeutic regimen. Randomized patients were evaluated (as long as relapse had not occurred) at 4, 12, 24, and 36 weeks after randomization and thereafter 4 times a year (first year), twice a year (second year), and then once a year (third to fifth year) (eFigure 1 in Supplement 2). Relapse was defined as an mSWAT score of 1 or higher. When the clinical presentation was ambiguous, a skin biopsy specimen was taken for histologic examination. Details on patient inclusion and exclusion criteria, MPD determination, PUVA treatment, tissue sample collection and processing, histologic assessment, immunobead assay, quantitative polymerase chain reaction, flow cytometry, and CD3/CD28 stimulation are provided in eMethods in Supplement 2. The study was conducted from April 27, 2012, to July 27, 2018.
of the evaluable population. The primary end point was the median time to relapse in patients with CR randomized to PUVA maintenance or no maintenance. A sample size of 82 (including a dropout rate of 10%) was calculated using nQuery Advisor, version 4.0 (Statsols), assuming α = .05 and power = 0.8 for an effect size of 12-month prolongation of the diseasefree interval after CR. An accrual time of 24 months was assumed. Minimum follow-up was set to 12 months and the maximum follow-up to 60 months after CR and PUVA treatment completion. Secondary end points included the expression of Treg-related molecules in lesional tissue, the proliferative capacity of blood circulating T cells and serum cytokine levels to identify biomarkers that are associated with the response to PUVA treatment.
Kaplan-Meier analysis and log-rank tests were performed to determine disease-free survival. Unpaired or paired, 2-tailed t test, Mann-Whitney test, and χ2 or Fisher exact test, whichever was appropriate, was used to analyze certain clinical, histologic, and biomarker data. Hierarchical cluster analysis was conducted to determine the association coefficient for chemotactic mediator levels. The threshold for statistical significance was set to P < .05.
Results
Patients
Twenty-seven patients were enrolled in the study at the centers in Graz, Vienna, Hietzing, Innsbruck, or Salzburg, Austria, beginning March 13, 2013, and the last patient was enrolled on March 21, 2016 ( Figure 1 ). Enrollment was closed in August 2016 because of low accrual (after extension of the accrual period from 24 to 40 months), and the study was terminated in July 2018, when the last patient recruited had completed the minimum of 12 months of follow-up according to the trial protocol. Of the 27 patients, 19 (70%) were male and the mean (range) age was 61 (30-80) years. Baseline demographic and diagnostic details are listed in the Table. Previous treatments included phototherapy in 14 patients (UV-B: 6 [22%]; PUVA: 4 [15%]; and PUVA/UV-B: 4 [15%]). The patients received PUVA treatment twice a week for 12 to 24 weeks, depending on clinical response (eFigure 1 in Supplement 2). The phototherapeutic characteristics of the 26 patients who completed the minimum 12 weeks of the PUVA induction phase are depicted in eTable 1 in Supplement 2.
Clinical Treatment Response
Nineteen patients (70%) had CR, and 8 patients (30%) had PR (Table) , as defined by mSWAT score reduction of more than 50% (objective response rate of 100%). Patients received a maximum of 48 treatment sessions during the PUVA induction phase, with a similar cumulative mean dose of 78.5 J/cm Abbreviations: HT-TCR, high-throughput T-cell receptor; mSWAT, modified severity-weighted assessment tool; PUVA, psoralen-UV-A.
a Only 21 patients were tested for clonality by HT-TCR sequencing. Figure 3B ). The response rate increased along the length of the PUVA induction phase: By 12 weeks, the response rate was 19% (5 of 27 patients); after 14 to 16 weeks (9 of 27 patients), 33%; and by 20 weeks, 52% (14 of 27 patients). Among patients with PR, the mean mSWAT decreased 63%, from 16.8 to 3.9. All patients with CR were randomized to either PUVA maintenance or no maintenance. The mean percentages of body surface involvement and mSWAT values were similar at baseline (eFigure 2A in Supplement 2). Patients in arm A received a total UV-A dose (induction and maintenance phases) of 130.3 J/cm 2 . After the first 12 months from randomization, 7 (64%) of 11 patients in maintenance were in remission. In comparison, only 1 (13%) of 8 patients with no maintenance remained cleared (and within 20 months after randomization, all of them relapsed; Table) . In the maintenance group, 4 patients (36%) relapsed during maintenance; 5 patients (45%) relapsed after completing maintenance (months 13 to 31); and, at the closing date of the study, 2 patients (18%) were still in remission (1 for 49 months, and 1 for 54 months). The median (range) duration of disease-free remission (Table) was 15 (1-54) months in patients with maintenance compared with 4 (1-20) months in those without it (15 vs 4 months; P = .02; Figure 3C ). The hazard ratio for recurrence was 3.25 (95% CI, 1.14-9.29), comparing PUVA maintenance with no maintenance. These results indicate that PUVA maintenance extends the duration of disease-free remission in MF.
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Histopathologic Evaluation, Clonality, and Response
Blinded histopathologic reevaluation of all biopsy samples after study completion revealed an overall reduction in pathognomonic MF features scores (eFigure 2B in Supplement 2). At baseline, 18 patients (67%) had a score of 2 (high), and 9 patients (33%) had a score of 1 (low). The PUVA induction phase reduced this score to 0 (absent) in 17 patients (65%) and to 1 (low) in 6 patients (23%), but it did not reduce the score at all in 3 patients (23%). For infiltration density at baseline (eFigur e2CinSupplement 2), 15 patients (56%) had a score of 2 (high), and 12 patients (44%) had a score of 1 (medium).
After 12 to 24 weeks of PUVA therapy, infiltration density score was reduced to 0 (no/low) in 14 patients (54%) and to 1 (medium) in 6 patients (23%), but it was not reduced at all in 6 patients (23%). Low cellular infiltrate density at baseline was associated with CR to PUVA treatment. At baseline, 11 (58%) of 19 patients with CR had a density score of 1, compared with 1 (13%) of 8 patients with PR (11 of 19 vs 1 of 8; P = .04). However, after the PUVA induction phase, 15 (79%) of 19 patients with CR had a pathognomonic MF score of 0, compared with 2 (29%) of 7 patients with PR (15 of 19 vs 2 of 7; P = .03). The infiltration score was also reduced at least by 1 grade in 13 (69%) of 19 patients with CR after the PUVA induction phase, compared with 1 (14%) of 7 patients with PR (13 of 19 vs 1 of 7; P = .02).
Lesional biopsy specimens taken at baseline from 21 (78%) of 27 patients provided DNA of sufficient quality and quantity with which to perform high-throughput TCR sequencing, as previously described. 29 A predominant T-cell clone (a clonotype with a minimum 3-fold higher frequency of reads over the second most frequent TCR sequence) was detected in 15 (72%) of 21 patients. We found a predominant clone in 11 (65%) of 17 cases with CR and in all 4 (100%) of 4 patients with PR (Table) . Representative examples of TCR clonal analysis are shown in Figure 2 . A case of malignant clone depletion and decreased total T-cell infiltrate after the PUVA induction phase is shown in Figure 2A , and a case of failed depletion in a patient with a high percentage of malignant cells and high density of cell infiltrate is given in Figure 2B . At baseline, patients with pathognomonic MF score of 2 (eFigure 2D in Supplement 2) and an infiltration density score of 2 (eFigure 2E in Supplement 2) had a higher mean percentage of clonal TCR sequence of total reads that was inversely associated with therapeutic response (eFigure 2F in Supplement 2), suggesting that detectable levels of malignant clones may be associated with clinical outcome.
Effect of PUVA on T Cells
To assess the effects of PUVA on T cells and immune function, we evaluated skin biopsy specimens and blood samples taken at baseline and throughout treatment. In particular, we evaluated the expression of Treg-related markers in lesional skin and the proliferative capacity of T cells together with the percentage of Tregs in blood. Quantitative polymerase chain reaction analysis of CD3 and CD4 expression in lesional skin confirmed the decrease of lymphocytic infiltrate observed in hematoxylineosin (original magnification ×20) slides (eFigure 2B and C in Supplement 2). After 12 to 24 weeks of PUVA treatment, expression of CD3 and CD4 mRNA was statistically significantly lower than at baseline, reaching levels similar to those in normal skin controls (eFigure 3A in Supplement 2). We quantified the expression of CTLA-4, Foxp3, GITR, and TGF-β to characterize Tregs in skin and their change throughout PUVA treatment (see eTable 3 in Supplement 2). In general, the expression of each of these markers was higher in lesional 
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skin at baseline than in normal skin from donors. After 12 to 24 weeks, PUVA treatment statistically significantly reduced the expression of these markers to levels seen in normal skin (eFigure3AinSupplement 2). Biopsy specimens from patients with PR showed higher levels of CD3, CTLA-4, Foxp3, and GITR after PUVA treatment, indicating that residual infiltrating cells after A, Score on the modified severity-weighted assessment tool (mSWAT) was monitored throughout the duration (3-6 months) of the PUVA induction phase until randomization (month 0). Reduction of the mSWAT score to a value of 0 was defined in the trial protocol as complete response (n = 19). A substantial reduction of mSWAT values occurred also in patients who showed partial response (n = 8). B, This swimmer plot of the treatment course of each patient shows the length of the PUVA induction phase (dark blue), maintenance treatment (medium blue), and time in remission (light blue). The arrowheads indicate patients who had not yet relapsed (n = 2) at study termination. C, This Kaplan-Meier plot of disease-free remission shows a statistically significant (P =.02; calculated using log-rank test) difference between patients randomized to either PUVA maintenance or to no PUVA maintenance. PL indicates plaque; PT, patch.
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Original Investigation Research jamadermatology.com (Reprinted) JAMA Dermatology May 2019 Volume 155, Number 5 543 therapy had a Treg phenotype (eFigure 3B in Supplement 2). Analysis of T-cell proliferative capacity in cells from blood at baseline and throughout treatment showed that PUVA therapy reduced the response to CD3/CD28 stimulation, reaching statistical significance after 12 to 24 weeks of treatment (eFigure 4A in Supplement 2). Moreover, determination of Treg frequency in blood showed that PUVA treatment increased the percentage of Tregs from 6 weeks after start of treatment until termination of the PUVA induction phase (12-24 weeks; eFigure 4B in Supplement 2).
Biomarker Assessment
Using an immunobead array, we screened 65 proinflammatory analytes (eTable 2 in Supplement 2) in serum samples taken from patients at baseline. Nineteen markers were present at detectable levels (eTable 2 in Supplement 2) and selected for quantification throughout PUVA treatment (eFigure5inSupplement 2) to identify the association of serum biomarkers with clinical response. Multivariate analysis of samples taken from patients with CR and PR at baseline ( Figure 4 ) revealed a set of 6 cytokines and chemokines associated with clinical response. High levels of CXCL9, CXCL11, CXCL12, TNFSF13, and CXCL13 were negatively associated with clinical response ( Figure 4A ), with elevated absolute values in patients with PR ( Figure 4B ). The expression of TWEAK was directly associated with clinical response, with high levels of TWEAK in patients with CR. We detected high levels of soluble CD30 and CXCL13 in serum at baseline; however, both levels were statistically significantly decreased after 1 year of PUVA treatment (eFigure 5 in Supplement 2).
Discussion
In this study, twice-weekly PUVA treatment (starting with a relatively low dose of approximately 30% MPD) given for 12 to 24 weeks resulted in low cumulative UV-A doses (eTable 1 in Supplement 2) and led to a high CR rate of 70% (Table) . Subsequent use of standardized low frequency maintenance therapy prolonged disease-free remission. At the 12-month follow-up, 64% 
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Evaluation of Oral Psoralen-UV-A Treatment in Early-Stage Mycosis Fungoides of patients with PUVA maintenance were in remission and only 13% of those with no maintenance remained clinically cleared (7 of 11 vs 1 of 8; P = .03; Figure 3 ). In the short and intermediate term, this PUVA induction-maintenance regimen was safe and tolerated with minor adverse effects in a few cases. Consistent with a previous report in psoriasis, 33 twiceweekly PUVA treatment may be as effective as more frequent treatment in MF as well. In the present study, we had the theoretical concern of a decay in adaptive tolerance (achieved by steady UV-A dose increments in the induction phase) during the maintenance phase, considering the low frequency of sessions (intervals up to 4 weeks). However, this was not the case: Treatment-associated phototoxic erythema did occur in 12 (46%) of 28 patients during the induction phase and in 1 patient during both induction and maintenance. Compared with the results of other studies, the twice-weekly PUVA regimen of 12 to 24 weeks followed by 9-month maintenance resulted in a cumulative UV-A dose similar to a PUVA regimen of 3 or more sessions per week with no maintenance. Reports of other study protocols required UV-A doses higher than 180 J/cm 2 for treatment with no maintenance.
18,34
To date, this study is the first prospective randomized clinical trial that addresses the efficacy of low-dose, low-frequency oral PUVA and maintenance. 25 No clear evidence of the potential advantages of PUVA maintenance has been presented so far. 25 The reason may have been the unintentional skewing of results by nonrandomized treatment allocation by physicians, who often prescribe prolonged treatment with slow withdrawal (similar to PUVA maintenance) in cases of more severe disease. In a prospective study, 34 the CR rate after a maximum of 16 weeks of PUVA monotherapy (3 times/wk; 70% MPD starting dose) was 22.2% (10 of 45 patients) and the median time to relapse after CR was 9.7 months without maintenance. In comparison, this study's low-dose, low-frequency PUVA regimen for up to 24 weeks (2 times/wk; <50% MPD starting dose) had a superior CR rate of 70% (19 of 27 patients), and maintenance extended the median time to relapse from 4 to 15 months. Moreover, patients in this study received a substantially lower accumulated UV-A dose below 80.0 J/cm 2 , compared with the 107.0 J/cm 2 dose that patients received in the aforementioned study. 34 Whittaker et al 34 pointed out that the CR rate they observed for PUVA alone (and the combination of bexarotene and PUVA) was lower than the rates given in previous reports. 18 They suggested that this difference may have been the result of the use of rigorous assessment tools and shorter duration of PUVA therapy in their study (ie, median duration of 12 weeks). In the present study, the CR rate after 12 weeks was 19% (5 of 27 patients), after 14 to 16 weeks was 33% (9 of 27 patients), and after 20 weeks was 52% (14 of 27 patients) ( Figure 3B ), indicating that the length of PUVA treatment is crucial for the outcome. High infiltration density score at baseline associated with high frequency of malignant cells (eFigure 2E in Supplement 2) and subsequent clinical outcome (eFigure 2F in Supplement 2). Patients with a low proportion of clonal cells in lesional skin (Figure 2A ) tended to have better responses to PUVA than did those with a high proportion of clonal cells ( Figure 2B) . Moreover, the percentage of clonal TCR sequences associated with high pathognomonic MF features score (eFigure 2D in Supplement 2). All cases with PR but only 65% of cases with CR who were tested for high-throughput TCR sequencing showed clonality (Table) . Furthermore, patients with PR had a higher clonal read frequency (eFigure 2F in Supplement 2), indicating that the presence of malignant clones at detectable and high levels may be a marker of disease severity and associated with clinical failure, as previously suggested.
5,35
Previous reports have shown that Tregs inhabit lesional MF skin in early stages at similar levels to inflammatory skin diseases such as psoriasis and eczematous dermatitis. 36 In the present study, the residual infiltrate after treatment in patients with CR had low levels of Treg markers CTLA-4, Foxp3, and GITR, similar to healthy controls, whereas the residual infiltrate in patients with PR had a clear Treg phenotype (eFigure 3B in Supplement 2), going in line with the concept that Tregs in lesional skin promote an environment in which malignant cells can escape immune surveillance.
37
In MF, it is unclear whether the presence and proliferation of nonmalignant T cells with a diverse TCR repertoire suppress the overgrowth of malignant cells as observed in other T-cell malignant neoplasms 38 39 Although all patients in the present study had normal leukocyte levels in peripheral blood, most of them had a large number of soluble chemotactic factors with measurable levels in serum (eFigure 5 in Supplement 2). High levels of CXCL9, CXCL11, CXCL12, TNFSF13, and CXCL13 at baseline were negatively associated with clinical response (Figure 4 ). In contrast, the expression of TWEAK was directly associated with clinical response (ie, high levels of TWEAK at baseline associated with CR). The role of these mediators remains elusive; however, their chemotactic properties may have a role in counteracting the therapeutic effect of PUVA treatment. For instance, CXCL9 is a PU.1-regulated chemokine that was associated with therapeutic failure (ie, PR, Figure 4B ). In previous reports, this chemokine has been implicated in short- 45 Lactate dehydrogenase serum levels at baseline were within normal limits in all but 2 patients of the study; overall, they were not associated with clinical outcome as this has been previously observed only in patients with advanced disease stages.
46,47
Limitations
The major limitations of this study are the small overall sample size and the uneven distribution of the patients in different disease stages randomized to either PUVA maintenance or no maintenance ( Figure 3B ). The mean mSWAT score and percentage of body surface involvement, however, were similar in both arms of the study (eFigure 2A in Supplement 2).
Conclusions
Low-dose, low-frequency PUVA treatment resulted in a high rate of CR in MF, as assessed by clinical outcomes, histologic criteria, and high-throughput TCR sequencing. Certain soluble chemotactic factors (CXCL9, CXCL11-13, TNFSF13, and TWEAK) are potential biomarkers for therapeutic response to PUVA. Finally, PUVA maintenance treatment appears to be safe (at least at short and intermediate term) in MF, and patients benefit from extended disease-free intervals. 18 and 85 years old; had no anti-dsDNA and anti-Ro/La auto antibodies; had AST and SPGT levels < 2.5 × the upper limit of normal (ULN) and creatinine levels < 2 × ULN; had no evidence of severe cardiac insufficiency; had no serious illness/infection that could interfere with the planned treatment; and were in good health with a Karnofsky score > 60. All women of reproductive age had a pregnancy test; those who had a positive test result or were lactating were excluded from the study. Also excluded were patients who had received PUVA within 3 months before screening, had a photosensitive disease (including lupus erythematosus), or had a skin cancer syndrome such as basal cell nevus syndrome or xeroderma pigmentosum.
PUVA treatment
8-methoxypsoralen (8-MOP) was administered as a liquid preparation in soft gelatine capsules (Oxsoralen ® ; G.L. Pharma GmbH, Lannach, Austria). The standard dose was 1 capsule (10 mg 8-MOP) per 20 kg body weight (0.5mg/kg of bodyweight; maximal dose 70mg) given with food (preferentially dairy products) 1 h before UVA exposure. Before starting total body PUVA treatment, each patient's individual minimal phototoxic dose (MPD) was determined after ingestion of 8-MOP by applying a standard series of UVA doses to skin areas 1.5 cm in diameter (on the buttocks), as previously described.
30
The MPD was defined as the UVA dose producing slight homogenous erythema at the site of exposure at 72 h. The standard initial UVA dose of PUVA induction therapy was set to <50% of MPD. Patients were treated twice a week (on treatment weekdays at least 2 days apart). UVA radiation was delivered using Waldmann F85/100 W-PUVA fluorescent bulbs (Waldmann Medizintechnik, Villingen-Schwenningen, Germany) mounted in Waldman 7001 or similar cabinets. The UVA dose was increased weekly by 0-30%, depending on the absence or presence of erythema after preceding treatments. Dose was adjusted according to the skin's erythema response. Depending on the duration of the PUVA induction phase (3-6 months until CR or not), the patients received a total of 24-48 PUVA exposures according to the protocol. In Arm A, PUVA maintenance therapy was administered for 9 months in fixed UVA doses (each dose equal to the last dose before randomization) once weekly for 4 weeks, then once every 2 weeks for 8 weeks, and finally once every 4 weeks for 24 weeks. According to this protocol, patients were scheduled to receive a total of 14 PUVA exposures during the maintenance phase. Patients in Arm B did not receive PUVA maintenance.
Tissue sample collection and processing
When possible, biopsy samples were taken from a representative lesion at baseline (within 4 weeks before start of treatment) and after 12-24 weeks of PUVA treatment. A biopsy was taken from another area of the body if the clinical response to treatment on that side was ambiguous.
Skin samples were fixed in 4% formaldehyde and paraffin-embedded for histological and immunohistochemical analysis. A part of each skin sample was dispersed in RNAlater (Merck, Vienna, Austria) and thereafter stored at -80 C and transferred to the coordinating center for processing. Serum samples were collected at baseline and at 12-24 weeks and 1 year after start of PUVA, transferred to the coordinating center and analyzed simultaneously after completion of the study.
Histological assessment
Paraffin-embedded skin samples were sectioned ( (1) or high (2) . Infiltrate density was scored as no/low (0), medium (1), or high (2).
Immunobead assay
Serum cytokine levels were determined using a custom- 
T-cell characterization
High-throughput TCR (HT-TCR) sequencing was used to determine clonality on DNA extracted from lesional skin, as described previously. 31 For patients recruited in the coordinating center, Tcell proliferative capacity was determined by a tritiated thymidine ([ 
Patient Inclusion and Exclusion Criteria
Eligible patients had histologically confirmed early-stage MF (stage IA-IIA), 28, 29 were between 18 and 85 years old; had no anti-dsDNA and anti-Ro/La auto antibodies; had AST and SPGT levels < 2.5 × the upper limit of normal (ULN) and creatinine levels < 2 × ULN; had no evidence of severe cardiac insufficiency; had no serious illness/infection that could interfere with the planned treatment; and were in good health with a Karnofsky score > 60. All women of reproductive age had a pregnancy test; those who had a positive test result or were lactating were excluded from the study. Also excluded were patients who had received PUVA within 3 months before screening, had a photosensitive disease (including lupus erythematosus), or had a skin cancer syndrome such as basal cell nevus syndrome or xeroderma pigmentosum.
PUVA treatment
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Tissue sample collection and processing
Histological assessment
Paraffin-embedded skin samples were sectioned (3.5 m) and stained with H&E. Samples from all study centers were examined at the Dermatopathology Unit, Medical University of Graz (as the coordinating center) by an experienced histopathologist (LC) during the course of study and reports transmitted to the respective subinvestigators of the other centers. After completion of the study, available H&E skin sections were reevaluated in blinded, consensus-based fashion by three of the investigators (PV, PW, and LC). Cellular infiltration of lesional skin was assessed in biopsy samples taken at baseline (before PUVA was started) and at 12-24 weeks after PUVA at a body site, along with samples of normal skin available from the tissue bank of the Department of Dermatology (approval number: 18-068 ex 06/07). Pathognomonic MF features including epidermotropic cells and band-like dermal infiltrate with cerebriform cells were scored as absent (0) or present and, if present, as either low (1) or high (2) . Infiltrate density was scored as no/low (0), medium (1), or high (2).
Immunobead assay
Serum cytokine levels were determined using a custom-made panel of 19 analytes (ThermoFisher, Procartaplex PPX-19; Vienna, Austria). This panel was chosen after we had done a prescreening assay of 65 analytes (sTable2) in baseline serum samples from a subcohort of MF patients with known TCR clonality in the skin and found those 19 analytes at levels within the detection range of the assay. The Luminex 100/200 system (LX200-XPON3.1; Luminex Corp, Austin, TX, USA) was used to measure fluorescence and calculate absolute concentration of each analyte according to the manufacturer's instructions. Serum samples from healthy donors from another study (21-523 ex 09/10) were used as reference controls.
T-cell characterization
